Cargando…

CD24 Is a Prognostic Marker for Multiple Myeloma Progression and Survival

Surface antigens are commonly used in flow cytometry assays for the diagnosis of multiple myeloma (MM). Some of these are directly involved in MM pathogenesis or interactions with the microenvironment, but most are used for either diagnostic or prognostic purposes. In a previous study, we showed tha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gross Even-Zohar, Noa, Pick, Marjorie, Hofstetter, Liron, Shaulov, Adir, Nachmias, Boaz, Lebel, Eyal, Gatt, Moshe E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9144978/ https://www.ncbi.nlm.nih.gov/pubmed/35629039 http://dx.doi.org/10.3390/jcm11102913

Ejemplares similares

Understanding the Bioactivity and Prognostic Implication of Commonly Used Surface Antigens in Multiple Myeloma
por: Lebel, Eyal, et al.
Publicado: (2022)

Standardization of Molecular MRD Levels in AML Using an Integral Vector Bearing ABL and the Mutation of Interest
por: Nachmias, Boaz, et al.
Publicado: (2023)

The Emerging Role of Venetoclax-Based Treatments in Acute Lymphoblastic Leukemia
por: Aumann, Shlomzion, et al.
Publicado: (2022)

The role of CD24 in multiple myeloma tumorigenicity and effects of the microenvironment on its expression
por: Gilad, Nechama, et al.
Publicado: (2019)

Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed/refractory multiple myeloma: results from a phase I clinical trial
por: Asherie, Nathalie, et al.
Publicado: (2022)

Do older patients truly benefit from advances in myeloma care?
por: Gatt, Moshe E., et al.
Publicado: (2022)

Utility of Galactomannan Screening for Early Detection of Invasive Aspergillosis in High-Risk Hemato-Oncology Patients
por: Sabbah, Rozan, et al.
Publicado: (2023)

Clonal Myeloid Dysplasia Following CAR T-Cell Therapy: Chicken or the Egg?
por: Vainstein, Vladimir, et al.
Publicado: (2023)

COVID-19 Among Patients with Hematological Malignancies: Experience from a Tertiary Center Showing Lower Than Expected Mortality and Establishing the Safety of in-Hospital Patient Care during the Pandemic
por: Aumann, Shlomzion, et al.
Publicado: (2021)

Amyloidogenic light chains impair plasma cell survival
por: Pick, Marjorie, et al.
Publicado: (2023)

Monitoring Minimal Residual Disease in RUNX1-Mutated Acute Myeloid Leukemia
por: Nachmias, Boaz, et al.
Publicado: (2022)

Dose‐adjusted EPOCH‐R is not superior to sequential R‐CHOP/R‐ICE as a frontline treatment for newly diagnosed primary mediastinal B‐cell lymphoma: Results of a bi‐center retrospective study
por: Morgenstern, Yael, et al.
Publicado: (2021)

Predictors of death at home among cancer patients in Israel: a population-based study
por: Rottenberg, Yakir, et al.
Publicado: (2021)

P914: VENETOCLAX IN RELAPSE/REFRACTORY AL AMYLOIDOSIS- A MULTICENTER INTERNATIONAL RETROSPECTIVE REAL-WORLD STUDY
por: Lebel, Eyal, et al.
Publicado: (2023)

Early integration of palliative care for patients with haematological malignancies
por: Shaulov, Adir, et al.
Publicado: (2022)

Suppression of multiple myeloma by mitochondrial targeting
por: Aisen, Yana, et al.
Publicado: (2021)

Venetoclax in Relapse/Refractory AL Amyloidosis—A Multicenter International Retrospective Real-World Study
por: Lebel, Eyal, et al.
Publicado: (2023)

CD24 Expression is an Independent Prognostic Marker in Cholangiocarcinoma
por: Agrawal, Shefali, et al.
Publicado: (2007)

CD24 for Cardiovascular Researchers: A Key Molecule in Cardiac Immunology, Marker of Stem Cells and Target for Drug Development
por: Sagiv, Eyal, et al.
Publicado: (2021)

Soluble CD147 (BSG) as a Prognostic Marker in Multiple Myeloma
por: Łacina, Piotr, et al.
Publicado: (2022)

Direct fluorescent-dye labeling of α-tubulin in mammalian cells for live cell and superresolution imaging
por: Schvartz, Tomer, et al.
Publicado: (2017)

CD24, CD27, CD36 and CD302 gene expression for outcome prediction in patients with multiple myeloma
por: Alaterre, Elina, et al.
Publicado: (2017)

PVR (CD155) Expression as a Potential Prognostic Marker in Multiple Myeloma
por: Lee, Byung-Hyun, et al.
Publicado: (2022)

Targeted Therapy for HM1.24 (CD317) on Multiple Myeloma Cells
por: Harada, Takeshi, et al.
Publicado: (2014)

Targeting nuclear import and export in hematological malignancies
por: Nachmias, Boaz, et al.
Publicado: (2020)

CD24(+)/CD38(-) as new prognostic marker for non-small cell lung cancer
por: Karimi-Busheri, Feridoun, et al.
Publicado: (2013)

Identification of CD24 as a marker for tumorigenesis of melanoma
por: Tang, Ming-Rui, et al.
Publicado: (2018)

“Death is inevitable – a bad death is not” report from an international workshop
por: Shaulov, Adir, et al.
Publicado: (2019)

Mesenchymal stroma/stem cells: Haematologists’ friend or foe?
por: Nachmias, Boaz, et al.
Publicado: (2022)

P887: IN-HOUSE ANTI BCMA CAR-T THERAPY FOR THE TREATMENT OF RELAPSED REFRACTORY MULTIPLE MYELOMA: PHASE 1 RESULTS.
por: Asherie, N., et al.
Publicado: (2022)

Diagnostic and Management Difficulty of Bleeding Aorto-Duodenal Fistula Associated with Hodgkin’s Lymphoma
por: Nachmias, Boaz, et al.
Publicado: (2021)

Differential Function of a Novel Population of the CD19+CD24hiCD38hi Bregs in Psoriasis and Multiple Myeloma
por: Bartosińska, Joanna, et al.
Publicado: (2021)

CD24 is an independent prognostic marker of survival in nonsmall cell lung cancer patients
por: Kristiansen, G, et al.
Publicado: (2003)

SLUG/SNAI2 and Tumor Necrosis Factor Generate Breast Cells With CD44+/CD24- Phenotype
por: Bhat-Nakshatri, Poornima, et al.
Publicado: (2010)

Preclinical evaluation and structural optimization of anti-BCMA CAR to target multiple myeloma
por: Harush, Ortal, et al.
Publicado: (2022)

Significance of CD44 and CD24 as Cancer Stem Cell Markers: An Enduring Ambiguity
por: Jaggupilli, Appalaraju, et al.
Publicado: (2012)

Tuberculosis Incidence in HIV/AIDS Patients in Israel, 1983–2010
por: Mor, Zohar, et al.
Publicado: (2013)

Erratum to: ‘HIV prevalence in the Israeli tuberculosis cohort, 1999–2011’
por: Mor, Zohar, et al.
Publicado: (2016)

HIV prevalence in the Israeli tuberculosis cohort, 1999–2011
por: Zohar, Mor, et al.
Publicado: (2014)

Routine Inflammatory Markers Are Elevated in Myelodysplastic Syndromes at Presentation
por: Oster, Howard S., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_q345mjt9fiejjo5l24r8b6njcq